Overview
- Anvisa published a resolution in the Diário Oficial da União on Sept. 25, 2026, formally prohibiting consumer-directed advertising of Semavy after regulators found irregular promotions.
- Semavy is a GLP-1 medicine approved for inadequately controlled type 2 diabetes and is classified as a red‑striped prescription drug that must be sold only with retention of the medical prescription.
- The agency identified specific noncompliant promotions on electronic panels at São Paulo’s Congonhas Airport, on the product’s official website, and on social‑media profiles and videos.
- Anvisa cited Lei nº 6.360/1976 to justify the ban and has asked the manufacturer, Cosmed (part of Hypera Pharma), for a statement; Hypera told one outlet it is cooperating and has taken steps to adjust Semavy communications.
- The decision removes consumer-facing marketing that framed the product in weight‑loss terms and reinforces that prescription medicines may be promoted only to licensed health professionals, a move that could prompt closer scrutiny of GLP-1 advertising.